|
Session 136
Poster Abstracts
Resistance to New Antiretrovirals
Tuesday, 1-4 pm
Room: Hall B |
859
 |
Viral Resistance to the HIV-1 Maturation Inhibitor Bevirimat in the Context of a Protease that Confers Resistance to Protease Inhibitors
Catherine Adamson*1, K Waki1, S Ablan1, K Salzwedel2, and E Freed1
1NCI-Frederick, MD, US and 2Panacos Pharma, Inc, Gaithersburg, MD, US |
860
|
Characterization of Resistance Properties of a New Integrase Inhibitor S/GSK364735
Tomokazu Yoshinaga*1, K Nakahara1, M Kobayashi1, S Miki1, A Sato1, E Garvey2, S Foster2, M Underwood2, B Johns2, and T Fujiwara1
1Shionagi, Settsu, Japan and 2GlaxoSmithKline |
861
|
Effect of M184V, P119S, and T165A HIV-1 RT Mutations on Enzyme Behaviors and Viral Growth
Guangwei Yang*1, E Paintsil1, G Dutschman1, C J Wang1, H Tanaka2, M Baba3, and Y C Cheng1
1Yale Univ, New Haven, CT, US; 2Showa Univ, Tokyo, Japan; and 3Kagoshima Univ, Japan |
862
|
Co-receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists during a 14-Day Monotherapy Study with INCB9471
Susan Erickson-Viitanen*1, K Abremski1, K Solomon1, R Levy1, E Lam2, J Whitcomb2, R Lloyd, Jr.3, R Mathis3, J Reeves2, and D Burns3
1Incyte Corp, Wilmington, DE, US; 2Monogram Biosci, South San Francisco, CA, US; and 3Res Think Tank, Buford, GA, US |
863
|
Effect of Virus Concentration on in vitro Measurement of Phenotypic Resistance to the CCR5 Antagonist Vicriviroc
C Buontempo, R Ogert, L Ba, P Buontempo, L Wojcik, J Howe, R Ralston, and Julie Strizki*
Schering-Plough Res Inst, Kenilworth, NJ, US |
864
|
Detection of Viral Co-receptor Tropism Changes with a High-sensitivity Phenotypic Assay among HIV-infected Patients with Drug-resistant Viremia
Peter Hunt*1, S Deeks1, W Huang2, E Coakley2, D Han2, C Petropoulos2, M Bates2, R Hoh1, J Martin1, and J Reeves2
1Univ of California, San Francisco, US and 2Monogram Biosci, South San Francisco, CA, US |
865
|
Evaluating the Role of Etravirine in the Second-line ART after Failing an Initial NNRTI-based Regimens in a Resource-limited Setting
Somnuek Sungkanuparph*1, W Manosuthi2, S Kiertiburanakul1, B Piyavong1, and W Chantratita1
1Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand and 2Bamrasnaradura Infectious Diseases Inst, Ministry of Publ Hlth, Nonthaburi, Thailand |
866
|
Prevalence of TMC125 Resistance-associated Mutations in a Large Panel of Clinical Isolates
Gaston Picchio*1, J Vingerhoets2, M Staes3, L Tambuyzer2, L Bacheler4, T Pattery3, and M P de Bethune2
1Tibotec, Inc, Yardley, PA, US; 2Tibotec BVBA, Mechelen, Belgium; 3Virco BVBA, Mechelen, Belgium; and 4VircoLab Inc, Durham, NC, US |
867
|
Etravirine-resistance Mutations in Patients with Virologic Failure on Nevirapine or Efavirenz-based HAART
Babafemi Taiwo*1, B Chaplin2, J Stanton1, S Meloni2, S Akanmu3, W Gashau4, J Idoko5, I Adewole6, R Murphy1, and P Kanki2
1Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Lagos Univ Teaching Hosp, Nigeria; 4Univ of Maiduguri Teaching Hosp Nigeria; 5Jos Univ Teaching Hosp, Nigeria; and 6Univ Coll Hosp, Ibadan, Nigeria |
868
|
Prevalence of Mutations with Effect on Virological Response to Etravirine in Routine Clinical Samples
Josep Llibre*1, J Santos1, T Puig2, A Blanco2, R Paredes1, B Mothe1, and B Clotet1,2
1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA, Barcelona, Spain and 2IrsiCaixa Fndn, Barcelona, Spain |
|
